KDM6B and myeloid neoplasm: Together, these data suggest that heterozygous deletion of Kdm6b in Asxl1Y588XTg mice is sufficient to reverse the hematologic abnormalities due to ASXL1aa1–587 expression and prevent the progression of ASXL1aa1–587-mediated myeloid malignancies.